| Ident. | Authors (with country if any) | Title |
|---|
| 000043 |
Wai Kin D. Ko [France] ; Elsa Pioli ; Qin Li ; Steve Mcguire ; Audrey Dufour ; Todd B. Sherer ; Erwan Bezard ; Maurizio F. Facheris | Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. |
| 000075 |
Fanny Duval [France] ; Olivier Flabeau ; Julien Razafimahefa ; Umberto Spampinato ; François Tison | Encephalophaty associated with rasagiline and sertraline in Parkinson's disease: possible serotonin syndrome. |
| 000312 |
Adeline Gallini [France] ; Agnès Sommet [France] ; Anne-Marie Salandini [France] ; Patrick Veyssière [France] ; Jean-Louis Montastruc [France] ; Jean-Louis Montastruc [France] | Weight‐loss associated with anti‐dementia drugs in a patient with Parkinson's disease |
| 000353 |
Alexandre Castro-Caldas [Portugal] ; Paul Delwaide [Belgique] ; Wolfgang Jost [Allemagne] ; Marcelo Merello [Argentine] ; Adrian Williams [Royaume-Uni] ; Paolo Lamberti [Italie] ; Miguel Aguilar [Espagne] ; Susanna Del Signore [France] ; Pierre Cesaro [France] | The Parkinson–Control study: A 1‐year randomized, double‐blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease |
| 000371 |
Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Amos D. Korczyn [Israël] ; Peter P. De Deyn [Belgique] ; Carl E. Clarke [Royaume-Uni] ; Anthony E. Lang [Canada] ; Mona Abdalla [Royaume-Uni] | Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopa |
| 000450 |
Michael P. Hill [Royaume-Uni] ; Erwan Bezard [France] ; Steven G. Mcguire [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Ann Michel [Belgique] ; Renee Grimée [Belgique] ; Henrik Klitgaard [Belgique] | Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L‐dopa and ropinirole in the MPTP‐lesioned marmoset |
| 000455 |
Marc Ziegler ; Alexandre Castro-Caldas [Portugal] ; Susanna Del Signore [France] ; Olivier Rascol [France] | Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6‐month, randomized, placebo‐controlled study |
| 000508 |
Jean-Louis Montastruc [France] ; Karine Desboeuf [France] ; Maryse Lapeyre-Mestre [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Christine Brefel-Courbon [France] | Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease |
| 000518 |
Jean-Louis Montastruc [France] | Treatment of Parkinson's disease should begin with a dopamine agonist |
| 000535 |
Jean Louis Montastruc [France] ; Olivier Rascol [France] ; Jean-Michel Senard [France] | Treatment of Parkinson's disease should begin with a dopamine agonist |
| 000555 |
F. Le Doze [France] ; M. Moulin [France] ; G.-L. Defer [France] | Meige's syndrome in a patient treated with ranitidine |
| 000560 |
Korczyn [Israël] ; David J. Brooks [Royaume-Uni] ; Ehrout R. Brunt [Pays-Bas] ; Warner H. Poewe [Autriche] ; Olivier Rascol [France] ; Fabrizzio Stocchi [Italie] | Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study |
| 000598 |
Picard [France] ; A. De Saint-Martin [France] ; E. Salmon [Belgique] ; E. Hirsch [France] ; C. Marescaux [France] | Postencephalitic stereotyped involuntary movements responsive to L‐Dopa |
| 000601 |
Tison [France] ; L. Wiart [France] ; M. Guatterie [France] ; N. Fouillet [France] ; V. Lozano [France] ; P. Henry [France] ; M. Barat [France] | Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease |
| 000616 |
Jean-Louis Montastruc [France] ; Nelly Fabre [France] ; Olivier Blin [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; André Rascol [France] | Does fluoxetine aggravate Parkinson's disease? A pilot prospective study |
| 000619 |
Bonnet [France] ; I. Serre [France] ; R. Marconi [France] ; Yves Agid [France] ; B. Dubois [France] | A “combined” levodopa test as a useful method for evaluating the efficacy of dopamine agonists: Application to pergolide and bromocriptine |
| 000627 |
P. Krack [Allemagne] ; Marion [France] | “Apraxia of lid opening,” a focal eyelid dystonia: Clinical study of 32 patients |
| 000628 |
J. L. Montastruc [France] ; N. Fabre [France] ; Olivier Rascol [France] ; J. M. Senard [France] ; O. Blin [France] | N‐methyl‐D‐aspartate (NMDA) antagonist and Parkinson's disease: A pilot study with dextromethorphan |
| 000629 |
Rascol [France] ; Nelly Fabre [France] ; Olivier Blin [France] ; Janet Poulik [France] ; Umberto Sabatini [France] ; Jean-Michel Senard [France] ; Michèle Ané [France] ; Jean-Louis Montastruc [France] ; André Rascol [France] | Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease |
| 000647 |
H. Allain [France] ; Pierre Pollak [France] ; H. C. Neukirch [France] | Symptomatic effect of selegiline in De Novo Parkinsonian patients |
| 000654 |
Emre [Suisse] ; U. K. Rinne [Finlande] ; A. Rascol [France] ; A. Lees [Royaume-Uni] ; Yves Agid [France] ; X. Lataste [Suisse] | Effects of a selective partil D1 agonist, CY 208‐243, in de novo patients with Parkinson disease |
| 000677 |
J. L. Montastruc [France] ; Celsis [France] ; A. Agniel [France] ; J. F. Demonet [France] ; B. Doyon [France] ; M. Puel [France] ; J. P. Marc-Vergnes [France] ; A. Rascol [France] | Levodopa‐induced regional cerebral blood flow changes in normal volunteers and patients with Parkinson's disease |
